Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).
Metastatic Breast Cancer
DRUG: Paclitaxel Capsule|DRUG: IV Paclitaxel|DRUG: Encequidar tablet
Stage 1: Confirmed Tumor Response, Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria, 6 months|Stage 2: Confirmed Tumor Response, Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria, 1 Year
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).